
    
      This is a randomized, blinded, vehicle-controlled dose-escalation study. Initial enrollment
      and treatment will be conducted as an inpatient study. Patients will be randomized 2:1,
      ORTD-1 treatment versus vehicle control. Patients will be allocated into 1 of 3 sequential
      escalating dose cohorts. Blinded study drug will be infused intravenously once daily for 5
      consecutive days.
    
  